Acurx Pharmaceuticals, Inc.
- ACXP
- NASDAQ
- Biotechnology
- Antibiotic Development
- Infectious Disease
$1.14
Today +3.18%Quote Oct 19, 2026, 07:33 PM UTC
−20.86%over the last month
Max drawdown −20.9%From 1-month high −20.9%3 months −29.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
4
Market value
$6.3M
Quote Oct 19
Floor
$1.10
3.1% below price
Resistance
$1.17
3.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ACXPPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free